Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Adaptive clinical trials: overview 1
- Prof. Yu Shyr
-
2. Adaptive clinical trials: overview 2
- Prof. Yu Shyr
-
3. Bayesian adaptive designs for clinical trials
- Prof. Benjamin Saville
-
4. Adaptive clinical trial design: randomization
- Prof. Hao Liu
-
5. Adaptive designs for phase I trials 1
- Prof. Anastasia Ivanova
-
6. Adaptive designs for phase I trials 2
- Prof. Anastasia Ivanova
-
7. Case studies of adaptive early phase trials
- Prof. Daniel Normolle
-
8. Phase II clinical trials - traditional approaches
- Prof. Fei Ye
-
9. Phase II clinical trials - Bayesian methods
- Prof. Fei Ye
-
10. Seamless phase II/III trials
- Prof. Elizabeth Garrett-Mayer
- Mr. Nathaniel O’Connell
-
11. Frequentist approaches: sample size in adaptive clinical designs
- Prof. Tatsuki Koyama
-
14. Ethical issues in adaptive clinical trials
- Dr. Spencer Phillips Hey
-
15. Implementation of adaptive methods in early phase clinical trials
- Prof. Gina Petroni
-
16. Design early phase drug combination trials: methods
- Prof. Ying Yuan
-
17. Design early phase drug combination trials: software
- Prof. Ying Yuan
-
18. Adaptation in likelihood trials
- Prof. Jeffrey Blume
Printable Handouts
Navigable Slide Index
- Introduction
- Adaptive randomization: baseline covariates
- Adaptive minimization randomization
- Minimization randomization
- Minimization randomization (after 50 patients)
- Minimization randomization (51st patient)
- Minimization randomization (after 51 patients)
- Adaptive minimization randomization (example 2)
- Adaptive minimization randomization (outcome)
- Adaptive randomization: study outcome based
- Biased Urn
- Biased Urn model (1)
- Biased Urn model (2)
- ECMO background
- Response-adaptive randomization: ECMO
- Example (ECMO) - randomization scheme
- Example (ECMO) - results
- Biomarker-adaptive clinical trials design
- Prognostic marker
- Predictive marker
- Umbrella & basket trials
- Umbrella trial example
- Basket trial example: NCI match
- Summary
- Thank you
Topics Covered
- Adaptive randomization clinical trials: based on baseline covariates
- Adaptive minimization randomization
- Adaptive randomization clinical trials: based on study outcome
- Biased Urn
- Response-adaptive randomization: ECMO
- Example (ECMO)
- randomization scheme
- Biomarker-adaptive clinical trials design
- Prognostic marker
- Predictive marker
- Umbrella & basket trials
Talk Citation
Shyr, Y. (2017, August 31). Adaptive clinical trials: overview 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/FHZN3836.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Yu Shyr has no commercial/financial relationships to disclose
Adaptive clinical trials: overview 2
Published on August 31, 2017
27 min
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
This is the second half of the lecture one
about the overview about adaptive clinical trials.
0:09
Now, I'd like to talk about
adaptive randomization clinical trials based on the baseline covariates.
0:16
The one method I want to introduce to you is called, adaptive minimization randomization.
It's based on your baseline covariates,
balances treatments simultaneously over several prognostic factors.
We know very typically when we run a randomized trial,
we will use a stratified permuted block randomization.
But if you have a lot of prognostic factors you want to stratify,
then you may have a so-called sparse cell.
That is a different topic, so I don't want to cover it for this adaptive clinical trial.
But in the case of situations if you have a lot of prognostic factors,
or certain prognostic factors,
have a lot of different categories, a lot of levels.
For instance you say,
"Hey this prognostic factor,
I have age younger than 20,
20-30, 30-40, 40-50, it's just so sensitive to the age."
So therefore, I want to see if the treatment assignment balances
between A and B with respect to each age group,
but I have 10 age groups there.
Suppose this disease is very,
very sensitive to age.
In that case stratifying permuted block randomization
may not be an appropriate way to apply.
So, at that time, you need to think about using adaptive minimization randomization.
So, it does not balance within the cross-classified stratum cells,
it balances over the marginal totals.
So, the first thing I want all of you to understand,
if we use the minimization randomization,
you cannot guarantee for any particular prognostic factor.
As a balanced treatment assignment between A and B,
they must be within certain thresholds.
No, they cannot guarantee that!
But they will pretty much focus on the balance in the marginal totals,
instead of a variable, a particular strata.
So, in use, when the number of stratum cells is large,
you can see if I have
10 different prognostic factors and
they all have extremely important associations with my clinical outcome.
I want to see balance
simultaneously across all those 10 or large number of prognostics.
And not relatively say,
"Your sample size is small."
Then you may consider using minimization.